Coya Therapeutics, Inc.

NASDAQ:COYA

Biotechnology

Healthcare
$3.09 -3.18%

-$0.16 today

Market cap
$72.48M
Beta
0.62
P/E (TTM)
-3.9
EPS (TTM)
-$1.26
52W Low $3.71High $7.75

Volume 0.15M

Average 0.16M

COYA Pre-Tax Margin

Income before tax as a percentage of revenue.

Coya Therapeutics, Inc.NASDAQ: COYA

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -2869.6%

Pre-tax margin was -2869.6% in Q1 FY2026, down 36.3 pp from a year earlier. On a trailing-twelve-month basis it was -266.1%, up 218.5 pp year over year.

Context

  • Pre-tax margin widened in 1 of the last 2 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-2869.6%-2725.6 pp QoQ
Last fiscal yearDec 2025
-267.1%+171.9 pp YoY
LTMMar 2026
-266.1%+218.5 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-36.3 pp——
1 year+171.9 pp——
3 years———
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-267.1%
Year-over-year change
+171.9pp

Pre-Tax Margin vs competitors

How COYA compares with its peers on the latest reported figures

  • COYA's LTM Mar 2026 pre-tax margin of -266.1% is the 3rd highest of the 7 companies compared; the peer median is -313.8%.
  • Its year-over-year change of +218.5 pp is the 2nd highest of 6, against a peer median of -43.1 pp.
COYA Competitors Peer median
Pre-Tax Margin for COYA and competitors
Company Period LTM level YoY 3-year change
ORMPOramed Pharmaceuticals Inc.FY20253766.2% —+5159.6 pp
MGNXMacroGenics, Inc.LTM Mar 2026-45.2% -9.2 pp+29.5 pp
COYACoya Therapeutics, Inc.LTM Mar 2026-266.1% +218.5 pp—
WHWKWhitehawk Therapeutics IncFY2025-288.3% -43.1 pp+109.4 pp
OVIDOvid Therapeutics Inc.LTM Mar 2026-339.3% +4217.8 pp+3364.5 pp
STTKShattuck Labs, Inc.LTM Mar 2026-4987.4% -3454.4 pp+10754.8 pp
CLNNClene Inc.LTM Mar 2026-25009.7% -16703.7 pp-6761.3 pp
IMMXImmix Biopharma, Inc.FY2025— ——
ZNTLZentalis Pharmaceuticals, Inc.FY2025— ——
PLRXPliant Therapeutics, Inc.FY2025— ——
CNTXContext Therapeutics Inc.FY2025— ——
Peer median (excluding COYA) -313.8%-43.1 pp+1737.0 pp

Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue006M3.55M7.95M
Cost of Revenue04.41M5.5M11.87M27.36K
Gross Profit0(4.41M)500.68K(8.31M)7.92M
Gross Margin——8.3%-233.9%99.7%
Research & Development2.54M4.94M6.04M11.89M16.73M
Selling, General & Admin2.31M4.85M7.83M8.89M11.45M
Operating Expenses4.87M5.4M8.4M8.94M28.18M
Depreciation & Amortization16.13K27.36K27.36K27.36K27.36K
EBITDA(4.88M)(9.26M)(7.33M)(17.2M)(21.2M)
EBITDA Margin——-122.2%-483.9%-266.8%
Operating Income(4.87M)(9.81M)(7.9M)(17.25M)(20.27M)
Operating Margin——-131.7%-485.4%-255.0%
Interest Income00000
Interest Expense00000
Other Income / Expenses(21.48K)(2.43M)639.37K1.65M(957.4K)
Income Before Tax(4.89M)(12.24M)(7.26M)(15.6M)(21.22M)
Pre-Tax Margin——-121.0%-439.0%-267.1%
Income Tax Expense00723.85K(720.29K)3.09K
Net Income(4.89M)(12.24M)(7.99M)(14.88M)(21.23M)
Net Margin——-133.1%-418.7%-267.1%
EPS (Basic)(0.74)(1.23)(0.79)(0.98)(1.27)
EPS (Diluted)(0.74)(1.23)(0.79)(0.98)(1.27)
Weighted Avg Shares6.6M9.95M10.16M15.24M16.73M
Weighted Avg Shares (Diluted)6.6M9.95M10.16M15.24M16.73M

Coya Therapeutics, Inc.

NASDAQ:COYA

Intrinsic Alpha fair value

Locked

Current Price

$3.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.